"Designing Growth Strategies is in our DNA"

Radioligand Therapies Market Size, Share & Industry Analysis, By Product (Lutetium Lu 177 Vipivotide Tetraxetan, Lutetium Lu 177 Dotatate, and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors, and Others), By Target (Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor, and Others), By End User (Tertiary Care Academic/Comprehensive Cancer Centers, Specialized Nuclear Medicine Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: March 09, 2026 | Format: PDF | Report ID: FBI115467

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Incidence of Radioligand Therapies, By Key Countries
    2. Pipeline Analysis, By Key Players
    3. Regulatory Scenario, By Key Countries/Regions
    4. New Product Launches, By Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  5. Global Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. U.K.
      2. Germany
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Novartis AG
      2. Bristol-Myers Squibb Company
      3. AstraZeneca
      4. Eli Lilly and Company
      5. ITM Isotope Technologies Munich SE
      6. Telix Pharmaceuticals Limited
      7. Perspective Therapeutics
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Incidence of Radioligand Therapies, By Key Countries
    2. Pipeline Analysis, By Key Players
    3. Regulatory Scenario, By Key Countries/Regions
    4. New Product Launches, By Key Players
    5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  5. Global Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. U.K.
      2. Germany
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Radioligand Therapies Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Product
      1. Lutetium Lu 177 Vipivotide Tetraxetan
      2. Lutetium Lu 177 Dotatate
      3. Others
    2. Market Analysis, Insights and Forecast – By Indication
      1. Prostate Cancer
      2. Neuroendocrine Tumors
      3. Others
    3. Market Analysis, Insights and Forecast – By Target
      1. Prostate-Specific Membrane Antigen (PSMA)
      2. Somatostatin Receptor
      3. Others
    4. Market Analysis, Insights and Forecast – By End User
      1. Tertiary Care Academic/Comprehensive Cancer Centers
      2. Specialized Nuclear Medicine Centers
      3. Others
    5. Market Analysis, Insights and Forecast – By Country/Sub-Region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Novartis AG
      2. Bristol-Myers Squibb Company
      3. AstraZeneca
      4. Eli Lilly and Company
      5. ITM Isotope Technologies Munich SE
      6. Telix Pharmaceuticals Limited
      7. Perspective Therapeutics
Read Less

Figure 1:  Global Radioligand Therapies Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2:  Global Radioligand Therapies Market Value Share (%), by Product, 2025 & 2034

Figure 3:  Global Radioligand Therapies Market Value Share (%), by Indication, 2025 & 2034

Figure 4:  Global Radioligand Therapies Market Value Share (%), by Target, 2025 & 2034

Figure 5:  Global Radioligand Therapies Market Value Share (%), by End User, 2025 & 2034

Figure 6:  Global Radioligand Therapies Market Value Share (%), by Region, 2025 & 2034

Figure 7:  North America Radioligand Therapies Market Value (USD billion), by Product, 2025 & 2034

Figure 8:  North America Radioligand Therapies Market Value Share (%), by Product, 2025

Figure 9:  North America Radioligand Therapies Market Value (USD billion), by Indication, 2025 & 2034

Figure 10:  North America Radioligand Therapies Market Value Share (%), by Indication, 2025

Figure 11:  North America Radioligand Therapies Market Value (USD billion), by Target, 2025 & 2034

Figure 12:  North America Radioligand Therapies Market Value Share (%), by Target, 2025

Figure 13:  North America Radioligand Therapies Market Value (USD billion), by End User, 2025 & 2034

Figure 14:  North America Radioligand Therapies Market Value Share (%), by End User, 2025

Figure 15:  North America Radioligand Therapies Market Value (USD billion), by Country, 2025 & 2034

Figure 16:  North America Radioligand Therapies Market Value Share (%), by Country, 2025

Figure 17:  Europe Radioligand Therapies Market Value (USD billion), by Product, 2025 & 2034

Figure 18:  Europe Radioligand Therapies Market Value Share (%), by Product, 2025

Figure 19:  Europe Radioligand Therapies Market Value (USD billion), by Indication, 2025 & 2034

Figure 20:  Europe Radioligand Therapies Market Value Share (%), by Indication, 2025

Figure 21:  Europe Radioligand Therapies Market Value (USD billion), by Target, 2025 & 2034

Figure 22:  Europe Radioligand Therapies Market Value Share (%), by Target, 2025

Figure 23:  Europe Radioligand Therapies Market Value (USD billion), by End User, 2025 & 2034

Figure 24:  Europe Radioligand Therapies Market Value Share (%), by End User, 2025

Figure 25:  Europe Radioligand Therapies Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 26:  Europe Radioligand Therapies Market Value Share (%), by Country/ Sub-region, 2025

Figure 27:  Asia Pacific Radioligand Therapies Market Value (USD billion), by Product, 2025 & 2034

Figure 28:  Asia Pacific Radioligand Therapies Market Value Share (%), by Product, 2025

Figure 29:  Asia Pacific Radioligand Therapies Market Value (USD billion), by Indication, 2025 & 2034

Figure 30:  Asia Pacific Radioligand Therapies Market Value Share (%), by Indication, 2025

Figure 31:  Asia Pacific Radioligand Therapies Market Value (USD billion), by Target, 2025 & 2034

Figure 32:  Asia Pacific Radioligand Therapies Market Value Share (%), by Target, 2025

Figure 33:  Asia Pacific Radioligand Therapies Market Value (USD billion), by End User, 2025 & 2034

Figure 34:  Asia Pacific Radioligand Therapies Market Value Share (%), by End User, 2025

Figure 35:  Asia Pacific Radioligand Therapies Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 36:  Asia Pacific Radioligand Therapies Market Value Share (%), by Country/ Sub-region, 2025

Figure 37:  Latin America Radioligand Therapies Market Value (USD billion), by Product, 2025 & 2034

Figure 38:  Latin America Radioligand Therapies Market Value Share (%), by Product, 2025

Figure 39:  Latin America Radioligand Therapies Market Value (USD billion), by Indication, 2025 & 2034

Figure 40:  Latin America Radioligand Therapies Market Value Share (%), by Indication, 2025

Figure 41:  Latin America Radioligand Therapies Market Value (USD billion), by Target, 2025 & 2034

Figure 42:  Latin America Radioligand Therapies Market Value Share (%), by Target, 2025

Figure 43:  Latin America Radioligand Therapies Market Value (USD billion), by End User, 2025 & 2034

Figure 44:  Latin America Radioligand Therapies Market Value Share (%), by End User, 2025

Figure 45:  Latin America Radioligand Therapies Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 46:  Latin America Radioligand Therapies Market Value Share (%), by Country/ Sub-region, 2025

Figure 47:  Middle East & Africa Radioligand Therapies Market Value (USD billion), by Product, 2025 & 2034

Figure 48:  Middle East & Africa Radioligand Therapies Market Value Share (%), by Product, 2025

Figure 49:  Middle East & Africa Radioligand Therapies Market Value (USD billion), by Indication, 2025 & 2034

Figure 50:  Middle East & Africa Radioligand Therapies Market Value Share (%), by Indication, 2025

Figure 51:  Middle East & Africa Radioligand Therapies Market Value (USD billion), by Target, 2025 & 2034

Figure 52:  Middle East & Africa Radioligand Therapies Market Value Share (%), by Target, 2025

Figure 53:  Middle East & Africa Radioligand Therapies Market Value (USD billion), by End User, 2025 & 2034

Figure 54:  Middle East & Africa Radioligand Therapies Market Value Share (%), by End User, 2025

Figure 55:  Middle East & Africa Radioligand Therapies Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 56:  Middle East & Africa Radioligand Therapies Market Value Share (%), by Country/ Sub-region, 2025

Figure 57:  Global Radioligand Therapies Market Share (%), by Company, 2025

Table 1:  Global Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 2:  Global Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 3:  Global Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 4:  Global Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 5:  Global Radioligand Therapies Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 6:  North America Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 7:  North America Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 8:  North America Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 9:  North America Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 10:  North America Radioligand Therapies Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 11:  Europe Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 12:  Europe Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 13:  Europe Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 14:  Europe Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 15:  Europe Radioligand Therapies Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 16:  Asia Pacific Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 17:  Asia Pacific Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 18:  Asia Pacific Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 19:  Asia Pacific Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 20:  Asia Pacific Radioligand Therapies Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 21:  Latin America Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 22:  Latin America Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 23:  Latin America Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 24:  Latin America Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 25:  Latin America Radioligand Therapies Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 26:  Middle East & Africa Radioligand Therapies Market Revenue (USD billion) Forecast, by Product, 2021–2034

Table 27:  Middle East & Africa Radioligand Therapies Market Revenue (USD billion) Forecast, by Indication, 2021–2034

Table 28:  Middle East & Africa Radioligand Therapies Market Revenue (USD billion) Forecast, by Target, 2021–2034

Table 29:  Middle East & Africa Radioligand Therapies Market Revenue (USD billion) Forecast, by End User, 2021–2034

Table 30:  Middle East & Africa Radioligand Therapies Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Radioligand Therapies Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 160
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Get 20% Free Customization On This Report
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports